Cargando…
Natural product myricetin is a pan-KDM4 inhibitor which with poly lactic-co-glycolic acid formulation effectively targets castration-resistant prostate cancer
BACKGROUND: Castration-resistant prostate cancer (CRPC) with sustained androgen receptor (AR) signaling remains a critical clinical challenge, despite androgen depletion therapy. The Jumonji C-containing histone lysine demethylase family 4 (KDM4) members, KDM4A‒KDM4C, serve as critical coactivators...
Autores principales: | Liu, Jai-Shin, Fang, Wei-Kai, Yang, Shan-Min, Wu, Meng-Chen, Chen, Tsan-Jan, Chen, Chih-Ming, Lin, Tung-Yueh, Liu, Kai-Lun, Wu, Chien-Ming, Chen, Yun-Ching, Chuu, Chih-Pin, Wang, Ling-Yu, Hsieh, Hsing-Pang, Kung, Hsing-Jien, Wang, Wen-Ching |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9082844/ https://www.ncbi.nlm.nih.gov/pubmed/35534851 http://dx.doi.org/10.1186/s12929-022-00812-3 |
Ejemplares similares
-
KDM4B is a coactivator of c-Jun and involved in gastric carcinogenesis
por: Wu, Meng-Chen, et al.
Publicado: (2019) -
Targeting KDM4B that coactivates c-Myc-regulated metabolism to suppress tumor growth in castration-resistant prostate cancer
por: Wu, Meng-Jen, et al.
Publicado: (2021) -
Histone Demethylase KDM4C Stimulates the Proliferation of Prostate Cancer Cells via Activation of AKT and c-Myc
por: Lin, Ching-Yu, et al.
Publicado: (2019) -
KDM4B as a Target for Prostate
Cancer: Structural
Analysis and Selective Inhibition by a Novel Inhibitor
por: Chu, Chia-Han, et al.
Publicado: (2014) -
Inhibition of KDM4C/c‐Myc/LDHA signalling axis suppresses prostate cancer metastasis via interference of glycolytic metabolism
por: Lin, Ching‐Yu, et al.
Publicado: (2022)